-
Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.
Nucleic acids research 20161201
-
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Cell reports 20161122
-
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
The New England journal of medicine 20160707
-
Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
Toxicology letters 20160226
-
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Journal of medicinal chemistry 20150910
-
Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage.
Proceedings of the National Academy of Sciences of the United States of America 20140916
-
Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.
Cell metabolism 20140603
-
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters 20130801
-
Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
Molecular pharmacology 20121001
-
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Molecular pharmacology 20120801
-
Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine.
Molecular therapy : the journal of the American Society of Gene Therapy 20120501
-
Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
Hypertension (Dallas, Tex. : 1979) 20120501
-
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120315
-
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120315
-
The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation.
Cellular and molecular life sciences : CMLS 20120301
-
Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
The Journal of biological chemistry 20120203
-
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120115
-
Novel binding mode of a potent and selective tankyrase inhibitor.
PloS one 20120101
-
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
PloS one 20120101
-
Bortezomib-induced 'BRCAness' sensitizes multiple myeloma cells to PARP inhibitors.
Blood 20111208
-
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Cell cycle (Georgetown, Tex.) 20111201
-
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Cancer biology & therapy 20111115
-
Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
Oncology (Williston Park, N.Y.) 20111115
-
Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
Nuclear medicine communications 20111101
-
Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Cancer science 20111001
-
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Cancer research 20110901
-
Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
Cancer research 20110715
-
Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase.
Drug metabolism and disposition: the biological fate of chemicals 20110701
-
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.
Molecular cancer therapeutics 20110701
-
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
The Journal of clinical investigation 20110701
-
PARP inhibitors: its role in treatment of cancer.
Chinese journal of cancer 20110701
-
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20110601
-
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.
Nucleic acids research 20110501
-
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Neuro-oncology 20110501
-
5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).
Journal of medicinal chemistry 20110414
-
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
Cancer research 20110401
-
PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Acta clinica Belgica 20110101
-
Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
PloS one 20110101
-
Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
PloS one 20110101
-
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.
Nature structural & molecular biology 20101001
-
Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors.
Cancer research 20100801
-
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Cancer research 20100701
-
A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS.
Journal of pharmaceutical and biomedical analysis 20100501
-
Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
Biochemistry 20100216
-
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.
Cancer chemotherapy and pharmacology 20100201
-
Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100201
-
Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
Cancer journal (Sudbury, Mass.) 20100101
-
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
Breast cancer research : BCR 20100101
-
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 20091201
-
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
Journal of medicinal chemistry 20091112
-
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Cancer biology & therapy 20091101
-
Role of Phase 0 trials in drug development.
Future medicinal chemistry 20091101
-
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Molecular cancer research : MCR 20091001
-
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Molecular cancer therapeutics 20090801
-
Phase 0 trials: a platform for drug development?
Lancet (London, England) 20090718
-
Phase 0 clinical trials: an answer to drug development stagnation?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601
-
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601
-
Phase 0 trials for anticancer drug development.
Nature reviews. Drug discovery 20090601
-
Phase zero launch.
Nature biotechnology 20090601
-
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Molecular cancer therapeutics 20090201
-
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
Journal of medicinal chemistry 20090122
-
94th RSNA Annual Meeting.
The Lancet. Oncology 20090101
-
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 20081101
-
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Analytical biochemistry 20081015
-
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Molecular cancer research : MCR 20081001
-
Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080901
-
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20080801
-
Phase 0 trials: an industry perspective.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080615
-
Patient perspectives on phase 0 clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080615
-
Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage.
Cancer biology & therapy 20080601
-
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Anticancer research 20080101
-
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 20070515
-
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Clinical cancer research : an official journal of the American Association for Cancer Research 20070501
